{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:40:51Z","timestamp":1788273651430,"version":"build-2803163510"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The emergence of fentanyl in the setting of the US opioid crisis demands reconsideration of clinical approaches to buprenorphine initiation for patients with opioid use disorder (OUD), with the rationale that fentanyl\u2019s unique pharmacology leads to a greater risk of precipitated withdrawal (PW). Use of high-dose buprenorphine for initiation is a strategy that has been hypothesized to lead to less PW and better retention. In the absence of randomized clinical trials, it is important for clinicians to understand the evidence that suggests benefits of high-dose approaches while recognizing methodological limitations.<\/jats:p><\/jats:sec>Observations<\/jats:title>This article summarizes observational studies that have been published as of 2025 addressing key questions relevant to a high-dose buprenorphine approach. First, how common is PW with the standard-dose initiation of buprenorphine for persons who use fentanyl? Is the risk greater than for persons who do not use fentanyl? Second, is high-dose buprenorphine initiation associated with lower risk of PW compared with standard dose? Finally, is initiation of high-dose buprenorphine associated with better long-term treatment outcomes (greater retention and less health care utilization) compared with standard dose?<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Several recent studies provided a range of prevalence rates (1%-16%) for PW with buprenorphine initiation for persons with OUD using fentanyl, which may reflect differences in study design and setting. While certain studies described rates of PW that were 3 to 4 times higher among those with fentanyl use compared with those without, they were limited by low power due to the small number of PW events. Studies also did not provide clear evidence as to whether higher buprenorphine initiation is associated with lower risk of PW. Studies suggest higher retention and lower health care utilization with high dose vs the standard approach; however, there were methodologic problems due to observational study design, such as immortal time bias and unmeasured confounding. Evidence to inform clinicians\u2019 decisions whether to initiate buprenorphine treatment with high-dose strategies among patients who use fentanyl was limited, and more definitive studies are needed.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.28119","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:00:51Z","timestamp":1755788451000},"page":"e2528119","source":"Crossref","is-referenced-by-count":9,"title":["High-Dose Buprenorphine Treatment in the Setting of Fentanyl"],"prefix":"10.1001","volume":"8","author":[{"given":"Judith I.","family":"Tsui","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elenore P.","family":"Bhatraju","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A.","family":"Hallgren","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle"},{"name":"Department of Health Systems and Population Health, School of Public Health, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac C.","family":"Rhew","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[{"name":"Section of General Internal Medicine, Department of Medicine, Boston University Chobanian and Avedisian School of Medicine\/Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"8","key":"zsc250002r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25999","article-title":"Buprenorphine prescribing characteristics following relaxation of X-waiver training requirements.","volume":"7","author":"Christine","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zsc250002r5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jsat.2009.08.001","article-title":"Home- versus office-based buprenorphine inductions for opioid-dependent patients.","volume":"38","author":"Sohler","year":"2010","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"zsc250002r6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/ADM.0000000000000952","article-title":"A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era.","volume":"16","author":"Sue","year":"2022","journal-title":"J Addict Med"},{"key":"zsc250002r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108147","article-title":"Protracted renal clearance of fentanyl in persons with opioid use disorder.","volume":"214","author":"Huhn","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"zsc250002r8","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A neuropharmacological model to explain buprenorphine induction challenges.","volume":"80","author":"Greenwald","year":"2022","journal-title":"Ann Emerg Med"},{"key":"zsc250002r9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ajem.2022.05.013","article-title":"Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting.","volume":"58","author":"Spadaro","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"4","key":"zsc250002r10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/ADM.0000000000000945","article-title":"Low dose initiation of buprenorphine: a narrative review and practical approach.","volume":"16","author":"Cohen","year":"2022","journal-title":"J Addict Med"},{"issue":"6","key":"zsc250002r11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1080\/15563650.2022.2032730","article-title":"Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl.","volume":"60","author":"Spadaro","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"zsc250002r12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/ebmed-2016-110401","article-title":"New evidence pyramid.","volume":"21","author":"Murad","year":"2016","journal-title":"Evid Based Med"},{"issue":"4","key":"zsc250002r13","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/ADM.0000000000000922","article-title":"Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl.","volume":"16","author":"Varshneya","year":"2022","journal-title":"J Addict Med"},{"issue":"1","key":"zsc250002r14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/add.16646","article-title":"Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: a systematic review.","volume":"120","author":"Gregory","year":"2025","journal-title":"Addiction"},{"issue":"3","key":"zsc250002r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.1572","article-title":"High-dose buprenorphine initiation in the emergency department among patients using fentanyl and other opioids.","volume":"6","author":"Snyder","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zsc250002r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35895","article-title":"Buprenorphine-precipitated withdrawal among hospitalized patients using fentanyl.","volume":"7","author":"Thakrar","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zsc250002r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.6108","article-title":"Incidence of precipitated withdrawal during a multisite emergency department\u2013initiated buprenorphine clinical trial in the era of fentanyl.","volume":"6","author":"D\u2019Onofrio","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zsc250002r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl.","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zsc250002r19","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/add.70002","article-title":"The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021.","volume":"120","author":"Stringfellow","year":"2025","journal-title":"Addiction"},{"issue":"9","key":"zsc250002r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35478","article-title":"Association of daily doses of buprenorphine with urgent health care utilization.","volume":"7","author":"Axeen","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zsc250002r22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-085888","article-title":"Randomised clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper.","volume":"14","author":"Armeni","year":"2024","journal-title":"BMJ Open"},{"issue":"1","key":"zsc250002r23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome.","volume":"31","author":"Fareed","year":"2012","journal-title":"J Addict Dis"},{"issue":"4","key":"zsc250002r24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/15271544241268386","article-title":"Xylazine in the unregulated drug market: an integrative review of its prevalence, health impacts, and detection and intervention challenges in the united states.","volume":"25","author":"Kyei","year":"2024","journal-title":"Policy Polit Nurs Pract"},{"key":"zsc250002r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111318","article-title":"Changes in injecting versus smoking heroin, fentanyl, and methamphetamine among people who inject drugs in San Diego, California, 2020-2023.","volume":"259","author":"Eger","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"7589","key":"zsc250002r26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/bmj.39070.527986.68","article-title":"When are randomised trials unnecessary? Picking signal from noise.","volume":"334","author":"Glasziou","year":"2007","journal-title":"BMJ"},{"issue":"7","key":"zsc250002r27","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jama.2020.9151","article-title":"Immortal time bias in observational studies.","volume":"325","author":"Yadav","year":"2021","journal-title":"JAMA"},{"key":"zsc250002r28","doi-asserted-by":"publisher","author":"Jain","journal-title":"Front Psychiatry","DOI":"10.3389\/fpsyt.2024.1401676"},{"key":"zsc250002r29","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001202","author":"Weimer","year":"2023","journal-title":"J Addict Med"},{"key":"zsc250002r1","unstructured":"National Center for Health Statistics. US overdose deaths decrease in 2023, first time since 2018. Updated May 15, 2024. Accessed February 6, 2025. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm"},{"key":"zsc250002r3","unstructured":"Substance Abuse and Mental Health Services Administration. Buprenorphine. Updated March 28, 2024. Accessed February 6, 2025. https:\/\/www.samhsa.gov\/substance-use\/treatment\/options\/buprenorphine"},{"key":"zsc250002r4","unstructured":"Substance Abuse and Mental Health Services Administration. Buprenorphine quick start guide. Accessed July 21, 2025. https:\/\/www.samhsa.gov\/sites\/default\/files\/quick-start-guide.pdf"},{"key":"zsc250002r21","unstructured":"Hawk? K, Herring? A, D\u2019Onofiro? G. Standard versus high dose ED-initiated buprenorphine induction (NIH HEAL Initiative). National Institute on Drug Abuse. Accessed February 6, 2025. https:\/\/nida.nih.gov\/about-nida\/organization\/cctn\/ctn\/research-studies\/standard-versus-high-dose-ed-initiated-buprenorphine-induction"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837844\/tsui_2025_sc_250002_1755115735.88752.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:00:52Z","timestamp":1755788452000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.28119","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}